Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

DNA Script launches a benchtop DNA printer

By Sean Whooley | June 24, 2021

DNA Script SYNTAXDNA Script announced the commercial launch of its Syntax platform with the Syntax system, a benchtop nucleic acid printer.

South San Francisco, Calif.-based DNA Script designed its Syntax system, a fully integrated, automated printer powered by enzymatic DNA synthesis (EDS) technology, to synthesize 96 DNA oligos in parallel, comprised of up to 60 nucleotides in length and delivers them ready for use in molecular biology and genomics workflows without the need for additional handling, according to a news release.

The system includes the benchtop DNA printer, reagent and consumable kits, along with management software. It requires less than 15 minutes of setup and synthesises 20mers in about six hours for same-day results, plus up to 60mers in about 13 hours to be efficiently run overnight.

Once synthesis completes, the Syntax printer purifies, quantifies and normalizes the oligos for seamless input into the next step of the research workflow. The software suite monitors reagent levels and enables the easy re-ordering of the Syntax kit.

DNA Script said that, with the launch, it now plans to accelerate the design-print-test cycle for assay optimization by enabling rapid, on-site synthesis of the DNA oligos for genomic workflows, including endpoint PCR, qPCR, amplicon sequencing and mutagenesis.

“The launch of the Syntax system delivers on our promise to develop and commercialize a benchtop instrument that provides unprecedented access to synthetic DNA and allows users unmatched shorter lead time, control and autonomy over their workflows,” DNA Script CEO and co-founder Thomas Ybert said in the release. “In just a few years, we have made rapid gains to improve enzymatic synthesis so that it performs comparably to, and in some cases better than, chemical synthesis, a 40-year-old technology, for molecular biology and genomics applications, which we see as just the beginning.”


Filed Under: Drug Discovery, Genomics/Proteomics
Tagged With: DNA Script
 

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE